Harvest Fund Management Co. Ltd Has $2.01 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

Harvest Fund Management Co. Ltd increased its position in DexCom, Inc. (NASDAQ:DXCM) by 42.5% in the fourth quarter, HoldingsChannel reports. The firm owned 26,307 shares of the medical device company’s stock after acquiring an additional 7,848 shares during the period. Harvest Fund Management Co. Ltd’s holdings in DexCom were worth $2,013,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DXCM. Versant Capital Management Inc acquired a new position in DexCom in the 4th quarter worth approximately $25,000. Private Trust Co. NA boosted its stake in DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares during the period. Larson Financial Group LLC boosted its stake in DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after purchasing an additional 137 shares during the period. Heck Capital Advisors LLC purchased a new stake in DexCom in the 4th quarter worth approximately $38,000. Finally, SBI Securities Co. Ltd. purchased a new stake in DexCom in the 4th quarter worth approximately $49,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DXCM opened at $73.38 on Thursday. The company has a market capitalization of $28.67 billion, a PE ratio of 51.31, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The company’s fifty day moving average price is $83.51 and its 200 day moving average price is $76.93.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Ratings Changes

DXCM has been the subject of a number of research analyst reports. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Canaccord Genuity Group increased their target price on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and increased their target price for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Finally, Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $99.82.

Insiders Place Their Bets

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the sale, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michael Jon Brown sold 13,000 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $914,940.00. Following the completion of the sale, the executive vice president now owns 105,602 shares in the company, valued at $7,432,268.76. This represents a 10.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 105,009 shares of company stock worth $8,044,178 in the last ninety days. Insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.